Related Experiment Video
Updated: Apr 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Toxicity of checkpoint inhibitors
1Medical Oncologist at Centro Oncológico Antonio Ermírio de Moraes, São Paulo, Brazil. schmerling@gmail.com.
Immunologic checkpoint inhibitor is a new class of antineoplastic drugs which mechanism of action depends on the interaction with the immune system. The first in class was ipilimumab, anti-CTLA4, and soon the anti-PD1 (Programmed Death 1) and anti-PDL1 are expected to be available. Although the profile of adverse events is unique, they are predictable and, by complying with the guidelines available, the management of these drugs is safe in the great majority of patients. Here, it is provided a review of adverse events and their management.
Immunologic checkpoint inhibitor is a new class of antineoplastic drugs which mechanism of action depends on the interaction with the immune system. The first in class was ipilimumab, anti-CTLA4, and soon the anti-PD1 (Programmed Death 1) and anti-PDL1 are expected to be available. Although the profile of adverse events is unique, they are predictable and, by complying with the guidelines available, the management of these drugs is safe in the great majority of patients. Here, it is provided a review of adverse events and their management.
More Related Videos
Related Concept Videos
Drug Toxicity: Dose-Dependent Reactions
Tumor Immunotherapy
Drug toxicity: Drug–Drug Interaction
Drug Toxicity: Allergic Reactions
Drug Toxicity: Overview
Drug Toxicity: Risk factors

